Chr. Hansen has appointed Cees de Jong as its new CEO, as Lars Frederiksen steps down from his post after eight years as CEO and 33 years with the company.
De Jong, a doctor of medicine, “brings a unique combined knowledge of ingredients and biopharmaceuticals”, chairman of the board Ole Andersen said in a statement. De Jong will take up the helm from April 1, after more than 20 years in a number of food ingredient and biopharmaceutical firms including DSM, Campina and Quest International. He was most recently chief operating officer at Crucell, a biopharmaceutical company acquired by Johnson & Johnson in 2011.
Frederiksen will step down “to dedicate more time to Board work” among other things, he said.
Frederiksen led the company’s transformation under the ownership of PAI Partners, and oversaw its listing on the Copenhagen stock exchange in 2010.